Skip to the answer

Carboplatin Uses, Dosage, Side Effects and Interactions

Brand names
Kyxata

Kyxata came 36 years after Paraplatin (August 2025) as an injection. The FDA rates no generic as a substitute for it.

First generic of Kyxata: our estimate, April 2045

Paraplatin

Paraplatin was the first carboplatin product the FDA approved, in March 1989. The FDA now lists it as discontinued; generic carboplatin is still listed.

Carboplatin is a platinum-based chemotherapy medicine given by injection to treat advanced ovarian carcinoma (ovarian cancer), both as first treatment and when the cancer has come back after earlier chemotherapy.

Dr. Brian Staiger, PharmD, BCPS
Last reviewed Jul 10, 2026 Content updated Nov 19, 2026 Where our facts come from

Quick links

Ask Anything About CarboplatinType a question in your own words. Answered from its FDA label in seconds.

Every other section of this page is in the dots on the left edge of your screen: point at one to see where it goes.Every other section of this page is one tap away: use the arrow tab on the left edge of your screen.

Carboplatin in Short

The Pharmacist’s Take

Dr. Brian Staiger, PharmD, BCPS
Clinical pharmacist Written

Carboplatin is a platinum chemotherapy drug that attaches to DNA inside cells and links its strands, so the cells cannot copy themselves and die; on the U.S. market since about 1989, with FDA-approved generics listed, it is a mainstay for advanced ovarian cancer, both as first treatment with other chemotherapy and when the cancer returns. It is usually easier to tolerate than its older relative cisplatin, but most people notice tiredness, some nausea and falling blood counts. Its boxed warning covers serious, sometimes life-threatening allergic reactions (anaphylaxis) that can start within minutes of an infusion in any cycle, so tell the nurse at once about itching, rash, wheezing or faintness.

Key Takeaways From the HelloPharmacist Team

  • Expect a clinic IV infusion on day 1 of each cycle, about every 4 weeks, usually up to 6 cycles for first treatment.
  • Plan on a blood test before every cycle, because your counts must recover first and your kidney function guides the dose.
  • Call your oncology team right away for fever, chills, or unusual bleeding or bruising, signs that low blood counts are causing trouble.
  • Take the antinausea medicine prescribed for after treatment on schedule, rather than waiting for nausea, and report vomiting you cannot control.

How we write and review this content: our editorial policy

FDA Boxed WarningThe FDA’s strongest safety alert. Read what it says about Carboplatin.

Kyxata can cause serious, life-threatening allergic reactions, including anaphylaxis. These can happen within minutes of an infusion, during any cycle. The label says treatment should be stopped or withheld for severe reactions and appropriate treatment given. Signs include rash, hives, itching, wheezing, low blood pressure and trouble breathing. Care teams give it where emergency equipment is available.

Read the full warning on DailyMed →

Carboplatin by the Numbers

Strengths
6
in one form
Makers and packagers
11
Earliest FDA record
1989
Rank by Medicaid prescriptions
#698 of 1,682 drugs
More prescriptions than 58% of the 1,682 drugs we measure
36,950 prescriptions, Q1–Q4 2025
Other forms and routes

Patient Information Guide for Carboplatin

What It’s Used For

Carboplatin is used for ovarian cancer in these situations:

  • Carboplatin injection: initial treatment of advanced ovarian cancer in combination with other approved chemotherapy, such as cyclophosphamide.
  • Carboplatin injection: palliative (symptom-relieving) treatment of ovarian cancer that returned after earlier chemotherapy, including after cisplatin.
  • Kyxata (intravenous): in adults, initial treatment of advanced ovarian cancer as part of a combination regimen.
  • Kyxata (intravenous): in adults, as a single agent for ovarian cancer that returned after earlier chemotherapy.

How It Works

Carboplatin is a platinum-based drug that binds to DNA and forms cross-links between its strands. These cross-links stop cells from copying and reading their DNA. That triggers processes that lead to cell death.

It works much like cisplatin, but it changes into its active form more slowly. That difference is linked to differences in potency.

Drug Class

Drug Class

  • Platinum-based Drug
Detailed classifications and sources

The FDA sorts a drug’s active ingredient by how it works, what it does in the body and its chemical structure, and gives it one main drug class.

Drug Class

Established Pharmacologic Class (EPC)
  • Platinum-based Drug

The main drug class the FDA gives it. It is the class named on the drug’s label.

How It Works

Mechanism of action (MoA)

None listed for Carboplatin in the FDA’s index.

What it does at the smallest level, such as a receptor or enzyme it blocks or switches on.

What It Does in the Body

Physiologic effect (PE)

None listed for Carboplatin in the FDA’s index.

From our Patient Information GuideCarboplatin is a platinum-based drug that binds to DNA and forms cross-links between its strands. These cross-links stop cells from copying and reading their DNA. That triggers processes that lead to cell death. Read How Carboplatin Works

A change it makes in how the body works.

Chemical Family

Chemical structure (CS)
  • Platinum-containing Compounds

The chemical family it belongs to, by its structure.

Drug Family

WHO ATC classification
  • Platinum compounds

How the World Health Organization groups it: by the part of the body it acts on and what it treats.

The classes are the FDA’s own words, from its index of drug labels, published in the National Library of Medicine’s RxClass. The description under What It Does in the Body is written by the HelloPharmacist team, not the FDA. Read the FDA’s definitions. The drug family is the World Health Organization’s ATC classification. Reference only, not medical advice.

Dosage

Carboplatin is given into a vein by a healthcare professional, so there is no food guidance and no missed doses to make up at home. Treatment usually runs in cycles of about 4 weeks, with a dose on day 1.

  • Combination treatment for first-line use is usually up to 6 cycles.
  • Single-agent treatment for recurrent cancer continues until the disease progresses or side effects become unacceptable (per the Kyxata label).
  • Doses may be based on body size or on kidney function, and are adjusted according to blood counts.

Follow your prescriber and the product label. Call your care team if you miss an appointment.

Typical Doses

Your prescriber chooses your dose, so take it exactly as prescribed.

Ovarian cancer

Adults with ovarian cancer that came back after earlier chemotherapy Usual dose 360 mg/m2 IV on day 1 every 4 weeks
  • 360 mg/m2 IV on day 1 every 4 weeks (alternatively see Formula Dosing)

Good to know

Not repeated until neutrophil count is at least 2,000 and platelet count is at least 100,000

IV means given into a vein (intravenous).

Adults with advanced ovarian cancer not yet treated Usual dose 300 mg/m2 of carboplatin IV on day 1 every 4 weeks

Step by step

  1. Carboplatin 300 mg/m2 IV on day 1 every 4 weeks for 6 cycles (alternatively see Formula Dosing)
  2. Cyclophosphamide 600 mg/m2 IV on day 1 every 4 weeks for 6 cycles

Good to know

Not repeated until neutrophil count is at least 2,000 and platelet count is at least 100,000

IV means given into a vein (intravenous).

Adults with advanced ovarian cancer not yet treated · Kyxata 300 mg/m2 Usual dose 300 mg/m2 on Day 1 every 4 weeks
  • Kyxata 300 mg/m2 OR AUC of 4 mg/mL∙min to 6 mg/mL∙min intravenously with cyclophosphamide 600 mg/m2 intravenously on Day 1 every 4 weeks for each cycle, up to six cycles or until disease progression or unacceptable toxicity

Good to know

For older adults, calculate dose based on AUC

Kyxata is a brand name for this medicine. See Kyxata’s full dosing instructions on DailyMed →

Adults with ovarian cancer that came back after earlier chemotherapy · Kyxata 360 mg/m2 Usual dose 360 mg/m2 on Day 1 every 4 weeks
  • Kyxata 360 mg/m2 OR AUC of 4 mg/mL∙min to 6 mg/mL∙min intravenously on Day 1 every 4 weeks for each cycle until disease progression or unacceptable toxicity

Good to know

For older adults, calculate dose based on AUC

Kyxata is a brand name for this medicine. See Kyxata’s full dosing instructions on DailyMed →

Adults with kidney problems, creatinine clearance 41 to 59 mL/min Usual dose 250 mg/m2 on day 1

Good to know

Applies to the initial course; later doses adjusted to bone marrow suppression

Adults with kidney problems, creatinine clearance 16 to 40 mL/min Usual dose 200 mg/m2 on day 1

Good to know

Applies to the initial course; later doses adjusted to bone marrow suppression

Adults, including older adults, previously treated Dose 4 mg/mL
  • Total Dose (mg) = (target AUC) × (GFR + 25)
  • Target AUC 4 mg/mL · min to 6 mg/mL · min

Good to know

Dose is in mg, not mg/m2; formula dosing should be used in elderly patients

GFR means glomerular filtration rate, a measure of how well the kidneys work.

Adults with mild kidney problems · Kyxata 89 mL No dose reduction

Kyxata is a brand name for this medicine. See Kyxata’s full dosing instructions on DailyMed →

Adults with kidney problems, creatinine clearance 41 to 59 mL/min · Kyxata 59 mL Usual dose 250 mg/m2 on Day 1

Kyxata is a brand name for this medicine. See Kyxata’s full dosing instructions on DailyMed →

Adults with kidney problems, creatinine clearance 16 to 40 mL/min · Kyxata 40 mL Usual dose 200 mg/m2 on Day 1

Kyxata is a brand name for this medicine. See Kyxata’s full dosing instructions on DailyMed →

Special Situations

If your test results change during treatment

Your doctor checks your test results during treatment and decides whether to change, pause or stop your dose. Never change your dose on your own.

  • Kyxata: Neutropenia, grade ≥ 4 ANC ≤ 0.5 x 10 9 / L, dose based on body surface area

    Interrupt Kyxata until ≤ Grade 1; reduce dose by 25%

  • Kyxata: Thrombocytopenia, grade ≥ 3 platelet count ≤ 50 x 10 9 / L, dose based on body surface area

    Interrupt Kyxata until ≤ Grade 1; reduce dose by 25%

ANC means absolute neutrophil count, the number of infection-fighting white blood cells.

See the Full Dosing Instructions on DailyMed →

Side Effects

Many people have side effects, and most are monitored with blood tests.

Common side effects

  • Low blood counts (low platelets, white cells and red cells/anemia)
  • Nausea and vomiting
  • Stomach pain, diarrhea or constipation
  • Tingling or numbness in hands and feet
  • Tiredness and weakness
  • Hair loss
  • Low levels of salts such as sodium, potassium, calcium and magnesium
  • Changes in liver or kidney blood tests
  • Low electrolytes (sodium, potassium, calcium, magnesium)

When to get medical help

  • Get help right away for signs of a severe allergic reaction: rash, hives, itching, wheezing, trouble breathing, or dizziness or faintness. These can happen within minutes of an infusion.
  • Tell your care team about fever, chills or signs of infection, since low white cells can make infections serious.
  • Report unusual bleeding or bruising, which can come from low platelets.
  • Report severe or uncontrolled vomiting.
  • Report new numbness, tingling or hearing changes.
  • Report vision loss, which has happened with doses higher than recommended.
  • Report pain, redness or swelling at the injection site.

Warnings and Precautions

  • Serious allergic reactions can happen within minutes, especially after earlier platinum treatment or after 6 cycles.
  • Bone marrow suppression can cause severe infections or bleeding. Blood counts are checked before each cycle.
  • Hemolytic anemia and hemolytic-uremic syndrome are rare, serious conditions. Treatment should stop at the first signs.
  • Severe vomiting can occur and is worse after previous emetogenic (vomiting-causing) therapy.
  • Nerve problems are more likely in people over 65 or previously treated with cisplatin.
  • Vision loss and severe liver problems have occurred with doses above those recommended.
  • Hearing loss has been reported in children at higher doses or with other hearing-toxic drugs.
  • It can harm an unborn baby.

Interactions

Carboplatin can add to the effects of other medicines.

  • Aminoglycoside antibiotics: higher risk of kidney and hearing problems.
  • Other kidney-harming drugs: carboplatin may increase kidney effects.
  • Phenytoin or fosphenytoin: levels may drop, which may worsen seizures.
  • Other bone marrow-suppressing drugs or radiation: blood count effects may add up.

Interactions Listed in the FDA-Approved Label

From the Carboplatin prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.

  • Nephrotoxic compounds
    What happensThe renal effects of nephrotoxic compounds may be potentiated by carboplatin.
  • Phenytoin/fosphenytoin
    What happensA decrease in phenytoin serum levels has been observed with concurrent carboplatin, which may lead to exacerbation of seizures.
Read the label’s full interactions text

Drug Interactions The renal effects of nephrotoxic compounds may be potentiated by carboplatin. A decrease in phenytoin serum levels has been observed with concurrent administration of carboplatin and phenytoin/fosphenytoin. This may lead to exacerbation of seizures.

Read the full Drug Interactions section on DailyMed →

Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.

Before You Start

  • Do not use if you have had a severe allergy to cisplatin, other platinum drugs, or mannitol.
  • Not for severe bone marrow depression or significant bleeding.
  • Tell your doctor about kidney problems, since dose changes may be needed.
  • Pregnancy: it can harm a baby. Pregnancy status should be checked first and effective contraception used.
  • Breastfeeding: Kyxata advises not breastfeeding during treatment and for 1 week after.
  • Older adults: higher risk of low platelets and nerve problems. Doses are based on kidney function.
  • Children: safety and effectiveness have not been established for Kyxata.

Overdose

There is no known antidote for overdose. Expected problems are bone marrow suppression and liver toxicity, and loss of vision or hearing loss in children have been reported at high doses. Kyxata is removed by dialysis, and patients are monitored closely and given supportive care.

Half-Life and How Your Body Processes It

Carboplatin levels in the blood fall in two phases after an infusion. Early half-lives were about 1 to 2 hours and later ones about 2.6 to 5.9 hours. Carboplatin itself is not bound to plasma proteins, though platinum from it binds irreversibly to proteins and clears slowly (half-life at least 5 days).

The kidneys do most of the clearing. In people with good kidney function, about 71% of a dose is in the urine within 24 hours. Kidney function strongly affects clearance, so doses are lowered when kidney function is reduced.

Storage

Unopened vials of carboplatin injection are stable to the date indicated on the package when stored at 20° to 25°C (68° to 77°F) . PROTECT FROM LIGHT.

Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI

Carboplatin: Pharmacist Answers to Common Questions

Quick, plain-English answers to the questions patients ask most about Carboplatin — the kind of thing our pharmacy team would talk through with you at the counter.

What is carboplatin used for?

Carboplatin treats advanced ovarian cancer. It is used with other chemotherapy as first treatment, and also for ovarian cancer that has come back after earlier chemotherapy. Your oncology team decides which approach fits you.

How is carboplatin given, and how often?

It is given as an IV infusion by your healthcare team, often over 15 minutes or longer. Treatment is usually on day 1 of a cycle that repeats about every 4 weeks. Your team sets the exact plan, and you will have blood tests before cycles.

What happens if I miss a carboplatin appointment?

Call your oncology team as soon as you can to reschedule. Do not try to catch up on your own. They will decide the timing based on your blood counts and treatment plan.

What side effects should I expect, and when should I call?

Nausea, vomiting, tiredness, hair loss and low blood counts are common, and antinausea medicine is given to help. Call right away for fever, signs of infection, unusual bleeding, severe vomiting, new numbness or tingling, or hearing or vision changes. Get emergency help for trouble breathing, hives, or feeling faint during or after an infusion.

Can I take carboplatin if I have kidney problems?

Your doctor may need to lower the dose, because the kidneys clear carboplatin and low kidney function raises the risk of low blood counts. Make sure your team knows about any kidney issues and other medicines, including certain antibiotics.

Is carboplatin safe during pregnancy?

No. It can harm an unborn baby, so pregnancy status should be checked before treatment. Kyxata advises effective contraception during treatment and for 6 months after for women, and 3 months for men with female partners. Kyxata also advises not breastfeeding during treatment and for 1 week after.

Is carboplatin available over the counter?

No. Carboplatin is a prescription medicine: every carboplatin product listed with the FDA is prescription only, so it is not sold over the counter. Your prescriber decides whether it is appropriate for you, and your pharmacist dispenses it.

When was carboplatin first available?

The earliest FDA record we hold for carboplatin is from 1989: its first approval in Drugs@FDA or its earliest product listing in the NDC Directory, whichever is older. Many older medicines were in use before their first formal FDA approval, so this is the earliest date on record, not necessarily when carboplatin was first used.

Who makes carboplatin?

11 companies currently list carboplatin products in the FDA's NDC Directory, including Hospira, Inc., BPI Labs LLC, Eugia US LLC. That count includes repackagers and distributors as well as manufacturers (companies that sell only the raw ingredient are not counted), so fewer companies actually make it; the label on your bottle names the one that supplied yours.

What is the brand name of carboplatin?

Carboplatin is the generic name. Its brand names are Kyxata and Paraplatin. Generic versions are listed under the name carboplatin.

What is the generic name of Kyxata?

The generic name of Kyxata is carboplatin. A generic name is the name of the active ingredient, the same whichever company makes the medicine; a brand name belongs to one company. Your prescription label may show either name.

What drug class is carboplatin?

Carboplatin belongs to the drug class Platinum-based Drug, its established pharmacologic class on the FDA label.

Is there a generic version of carboplatin?

Yes. FDA-approved generic versions of carboplatin are listed in the FDA's National Drug Code Directory. A listing does not prove that every pharmacy stocks one, so your pharmacy can tell you which version it carries.

What strengths does carboplatin come in?

Carboplatin is listed in the FDA's National Drug Code Directory in these forms and strengths. Injection (into a vein): 50 mg/5 mL, 80 mg/8 mL, 150 mg/15 mL, 450 mg/45 mL, 500 mg/50 mL and 600 mg/60 mL. A listing does not mean every pharmacy stocks every strength.

Is there a carboplatin shortage?

Yes. Carboplatin is on the FDA's drug shortage list as of Nov 22, 2026. A shortage means some products are hard to get, not that every pharmacy is out. The shortage page lists the affected products and what each company has told the FDA. Read the carboplatin shortage page

Where can I read the carboplatin prescribing information (package insert)?

The full FDA-approved prescribing information for carboplatin, also called the package insert or drug label, is published on DailyMed, the National Library of Medicine's library of FDA labels. Each company's version has its own label; this page is built from Avyxa Pharma, LLC's, revised Nov 9, 2026, and links to it on DailyMed.

Is carboplatin gluten free?

No carboplatin label we read lists an ingredient made from wheat, barley or rye, the grains that carry gluten, and none names a starch, dextrin or maltodextrin without saying where it comes from. We read the FDA labels of 33 carboplatin products from 10 companies. A label lists ingredients; it is not a gluten test, so we cannot promise that any product has no gluten. If you have celiac disease, ask the company for a written gluten statement. Our Inactive Ingredient Checker shows each company's carboplatin by strength and NDC, and whether its label lists a gluten source, lactose, dyes or any other inactive ingredient. See carboplatin inactive ingredients by company

Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI

Ask Anything About Carboplatin

Skip the scrolling. Ask in your own words and get an answer from Carboplatin’s FDA label and our pharmacists’ own work.

Try:

Name another drug or a supplement in your question and we check both.

AI answers from FDA labels and our own records, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.How this works
  • Sources: Carboplatin’s FDA label, including the clinical studies it reports, and the label of any drug you name; our pharmacists’ own work, such as our Do Not Crush list and our published answers to readers’ questions; our pharmacy prices and the Natural Medicines supplement database.
  • Written by AI: Answers are written by AI from those sources, and AI can make mistakes. Check what you read here with your doctor or pharmacist before you act on it.
  • Reviewed afterward: Our pharmacy team reviews every question and answer afterward to check it for accuracy, and when we find an error, we correct how the box answers. Read more in How we use AI.
  • Not medical advice. In an emergency, call 911, Poison Control at 1-800-222-1222, or 988.

More About Carboplatin on HelloPharmacist

Still have a question? A licensed pharmacist answers for free, as soon as they can.
Detailed Data & References for Carboplatin Forms and strengths, pricing, billing codes, manufacturers, safety reports and sourcing: the data behind the page. Most people can stop here. Each section below opens on a tap.

Carboplatin Forms and Strengths (How It Comes)

Carboplatin comes in 1 dose form, the injection. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.

Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Carboplatin inactive ingredients by manufacturer.

Injection

Into a vein
Brands Kyxata (2025) Paraplatin (the first brand, 1989, discontinued)
How this form is used
What it may be used for
  • Carboplatin injection is used for initial treatment of advanced ovarian cancer with other approved chemotherapy, and for ovarian cancer that returned after earlier chemotherapy.
  • Kyxata is used in adults for initial treatment of advanced ovarian cancer as part of a combination, and alone for recurrent ovarian cancer.
Important instructions
  • Carboplatin injection is usually given as an infusion lasting 15 minutes or longer.
  • Carboplatin injection must not contact needles or IV sets with aluminum parts.
  • Kyxata is given intravenously on day 1 of each cycle, about every 4 weeks, in a setting where emergency resuscitation equipment is available.
  • Kyxata patients receive antinausea medicine before each infusion.
Available strengths 7 strengths
Show 1 more strength Show fewer strengths
34 FDA-listed product records ⓘ

Carboplatin on the U.S. Market: Products, Makers and Brands

How Carboplatin appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

11 companies list 34 Carboplatin product records with the FDA, mostly as injection; the earliest marketing or approval year on record is 1989. The one brand name in the directory today is Kyxata; the rest are generics.

1
Dose forms ⓘ
11
Labelers (makers, repackagers, distributors)
2
Brand names ⓘ
34
FDA-listed product records ⓘ
1989
Earliest FDA record ⓘ

Also listed with the FDA, not a patient dose form: Powder (7) — bulk drug substance and unfinished product sold to compounders and other manufacturers to finish, and multi-item kits. These aren’t counted in the dose-form total above.

Hospira, Inc.15%
BPI Labs LLC12%
Eugia US LLC12%
Gland Pharma Limited12%
Natco Pharma USA LLC12%
Teva Parenteral Medicines, Inc.12%
Other makers26%

Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

How Widely Carboplatin Is Used (Medicaid Data)

How many Carboplatin prescriptions Medicaid paid for in Q1–Q4 2025, every brand, strength and form together. Medicaid is one program, so total U.S. use is higher.

36,950
Medicaid prescriptions filled (Q1–Q4 2025)
$6.1M paid by Medicaid, before rebates

How commonly is Carboplatin prescribed? Of the 1,682 medications we measure, Carboplatin ranks #698 by Medicaid prescriptions — more than 59% of them.

Where Carboplatin ranks among the drugs we measure · Q1–Q4 2025 · neighbors ±5

Utilization by Carboplatin product

Pick a strength and form to see its own numbers. Brand and generic versions are counted together.

carboplatin 10 MG/ML Injectable Solution

36,950 Medicaid prescriptions (Q1–Q4 2025) 100% of Carboplatin prescriptions shown $6.1M paid by Medicaid, before rebates ≈ $165 per prescription, before rebates

20 of 69 listed NDCs had Medicaid claims. RxNorm 597195

Dollars are what Medicaid paid before the rebates drug makers send back, so its real cost is lower.

Source: Medicaid State Drug Utilization Data (CMS), all states. 20 of the 69 listed Carboplatin NDCs had Medicaid claims.

Compare Carboplatin Products

A representative set of FDA-listed product records for Carboplatin — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Showing 34 of 34 products — FDA National Drug Code Directory. See every product, package size and price: browse all 34 Carboplatin NDCs →

Carboplatin Recall History

A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.

The FDA’s enforcement reports list no Carboplatin recalls since July 2021.

✅No Carboplatin recalls on record since July 2021

Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Nov 19, 2026.

Carboplatin in RxNorm: From Ingredient to Every Form and Strength

RxNorm is the U.S. National Library of Medicine’s standard name for every version of a medicine, the code pharmacy and prescribing systems share. This page starts from one ingredient (IN); each dose form (SCDF) branches from it, and each exact strength (SCD) from its form. Combination products are separate concepts with their own pages.

Dose forms
1
Strengths
1
Forms in current FDA listings
1 of 1
In current FDA listings No current FDA listing
Ingredient (IN) Carboplatin RxCUI 40048
  1. Dose form (SCDF) Injectable Solution RxCUI 378363
    In current FDA listings
    Its strength (SCD)

RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.

Carboplatin Brand Names

Carboplatin has 2 brand names on record: Kyxata and Paraplatin. Kyxata is in the FDA’s product directory today; Paraplatin is not. A brand name is one company's name for the medicine; a generic has the same active ingredient under its generic name.

Kyxata 2025 Paraplatin the first brand, 1989, discontinued

Who Makes Carboplatin: Manufacturers and Labelers

11 companies list Carboplatin products with the FDA. By number of product records, the largest are Hospira, Inc., BPI Labs LLC, Eugia US LLC. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.

Hospira, Inc. 5 BPI Labs LLC 4 Eugia US LLC 4 Gland Pharma Limited 4 Natco Pharma USA LLC 4 Teva Parenteral Medicines, Inc. 4 Teyro Labs Private Limited 4 Avyxa Pharma, LLC 2 Accord Healthcare, Inc. 1 Apotex Corp. 1 Fresenius Kabi USA, LLC 1

Sources for This Carboplatin Page

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. Prescribing information dated Nov 9, 2026, the label version this page reads. A label changes when the FDA approves new uses, doses or warnings, so this is not the day the page itself last changed. Read the full label on DailyMed
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Carboplatin.
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.

Where this information comes from

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 14 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source.

Clinical labels in scope
14
Finished products in the current FDA directory
34
Companies listing them (makers, repackagers, distributors)
11
FDA labeler codes behind them ⓘ
11
Linked representative label ⓘ
Avyxa Pharma, LLC
Linked label effective
Nov 9, 2026
Composite sections available
25
Linked SPL Set ID
f91c48da-68d1-4aa7-89b8-d84a3e8b629b
Linked SPL Document ID
abca9035-3ea6-421d-9ffb-07b7dee6cc28
Open the linked representative label on DailyMed ↗

How this page is built

HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Avyxa Pharma, LLC is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →